Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Source:http://linkedlifedata.com/resource/pubmed/id/19455328

Download in:

View as

Triples

General Info

PMID
19455328